NervAlign Nerve Cuff Eases Post-Surgery Pain

Jane Morgan Management

28 March 2025 | ReNerve Limited (ASX: RNV) ("ReNerve" or "the Company"), a medical device company focused on innovative products aimed at nerve repair and regeneration, is pleased to announce positive clinical data demonstrating the significant benefits of using the Company's NervAlign® Nerve Cuff in peripheral nerve repair surgery.

The study results, presented this week at the American College of Foot and Ankle Surgeons (ACFAS 2025) Annual Conference in Arizona, show that patients who underwent nerve repair surgery using the NervAlign® Nerve Cuff experienced a statistically significant reduction in post-surgical pain and greater patient satisfaction compared to those who underwent surgery without the Nerve Cuff.

Highlights

  • Pain scores decreased from a pre-operative average of 7.1 to 0.4 in patients treated with the NervAlign® Nerve Cuff, compared to a reduction from 7.1 to 3.3 in patients treated without the Nerve Cuff.

  • 93% of patients treated with the Nerve Cuff indicated they would elect to have the surgery again, compared to 70% in the non-cuff group.

  • The study demonstrated that the NervAlign® Nerve Cuff provides meaningful protection during nerve healing, leading to better long-term outcomes.

Commenting on the study, ReNerve CEO, Dr Julian Chick, stated: "These are very significant results for the development of ReNerve's products, as they highlight the utility of the NervAlign® Nerve Cuff in reducing patients' pain following peripheral nerve surgery. The results clearly demonstrate the patient benefits that follow from the proper repair and regeneration of a nerve that is returned to normal function post-surgery. The NervAlign® Nerve Cuff facilitates the patient's repair process is protected during the initial post-operative recovery and regeneration period. Thereafter, because the Nerve Cuff is absorbed naturally after six months, there is no longer a lasting 'foreign body' at the site of repair to create potential complications for the patient."

Study Design

  • Sample Size: 13 patients with the Nerve Cuff, 10 without

  • Gender: 21 Female, 2 Male

  • Average Age: 53

  • Average Follow-Up: 9.25 months

  • Endpoint Measures:

    • Visual Analogue Scale (VAS) for pain pre- and post-surgery

    • Willingness to repeat surgery as a proxy for patient satisfaction

About the NervAlign® Nerve Cuff

The NervAlign® Nerve Cuff is a bioabsorbable medical device designed to protect repaired nerves during the healing process following peripheral nerve surgery. It is absorbed naturally within six months, leaving no foreign material behind, and is suitable for use across a wide range of surgical procedures.

The study results further validate NervAlign® as a clinically meaningful innovation in nerve repair, with the potential to become a standard-of-care option for improving surgical outcomes and reducing patient discomfort post-operatively.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).